Cell Therapy To Prevent And Treat Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$260,302.00
Summary
In bone marrow transplantation, donor immunity can fight the cancer but can also attack healthy tissues, causing graft-versus-host disease (GVHD). We will use two types of cell therapy to treat GVHD. The first study will use a safety switch called inducible capase 9 (iCasp9) to enable the donor immune cells to be rapidly eliminated if GVHD occurs. The second study will use regulatory T cells to treat patients with chronic GVHD. If successful, these treatment approaches will make transplantation ....In bone marrow transplantation, donor immunity can fight the cancer but can also attack healthy tissues, causing graft-versus-host disease (GVHD). We will use two types of cell therapy to treat GVHD. The first study will use a safety switch called inducible capase 9 (iCasp9) to enable the donor immune cells to be rapidly eliminated if GVHD occurs. The second study will use regulatory T cells to treat patients with chronic GVHD. If successful, these treatment approaches will make transplantation safer.Read moreRead less
Regulatory T Cell Therapy For Prevention Of Graft Versus Host Disease
Funder
National Health and Medical Research Council
Funding Amount
$765,299.00
Summary
Graft versus host disease (GVHD) is a potentially fatal complication of bone marrow stem cell transplantation for leukaemia and lymphoma. In an animal model of GVHD, we have recently shown 100% effectiveness of treatment with a donor immune cell population, regulatory T cells. We will determine how this therapy works in the animal model. We will use a new technique, mass cytometry, to analyse patient blood samples in preparation for developing regulatory T cell therapy for GVHD.
Defining The In Vivo Contribution Of Leukocyte Extracellular Traps To Infective Disease
Funder
National Health and Medical Research Council
Funding Amount
$598,363.00
Summary
Neutrophils are the white blood cells that protect against infection. A surprising protective neutrophil behaviour was recently described – neutrophils can pack up their internal DNA and antimicrobial enzymes and explosively release them into their surrounds, forming a “Neutrophil Extracellular Trap” (NET). This project uses zebrafish built have fluorescent neutrophils to study NET release in living animals. We will learn how NETs control infection and what goes wrong when NETs cause disease.
Microenvironmental Regulation Of Blood Cells By Retinoic Acid Receptor Gamma.
Funder
National Health and Medical Research Council
Funding Amount
$958,428.00
Summary
Vitamin A deficiency causes profound effects in humans, with anaemia and an inability to fight infection being consequences of vitamin A deficiency on blood cells. We have evidence that these effects of vitamin A deficiency occur via one of the receptors for vitamin A. Furthermore, these effects are due to changes in the non-blood cells that help to make blood cells. By understanding how this occurs we may identify better treatments for patients with impaired immune systems.
IL-6 As The Key Inflammatory Mediator Controlling GVHD
Funder
National Health and Medical Research Council
Funding Amount
$592,049.00
Summary
Allogeneic haematopoietic stem cell transplantation (SCT) is a curative treatment for blood cancers. Graft-versus-host disease (GVHD) is a major limitation which occurs when the newly transplanted immune system mounts a rejection response against the recipient and is responsible for the death of up to 40% of transplant recipients. These studies will optimize a new approach to prevent GVHD focusing on a protein called interleukin-6. Ultimately, it is anticipated such approaches will improve the o ....Allogeneic haematopoietic stem cell transplantation (SCT) is a curative treatment for blood cancers. Graft-versus-host disease (GVHD) is a major limitation which occurs when the newly transplanted immune system mounts a rejection response against the recipient and is responsible for the death of up to 40% of transplant recipients. These studies will optimize a new approach to prevent GVHD focusing on a protein called interleukin-6. Ultimately, it is anticipated such approaches will improve the overall survival of patients with blood cancers.Read moreRead less